Mid-cap biotech catalysts: FDA dates, earnings, and pipeline data to watch
Five mid-cap biotechs are highlighted with upcoming catalysts. Cytokinetics (CYTK) awaits an FDA decision on Nov 14. Arrowhead (ARWR) reports earnings on Nov 12, while Ionis (IONS) saw a post-earnings sell-off. Crispr (CRSP) and Viking (VKTX) have undated catalysts. CYTK's Q3 revenue was $47.6M, beating estimates. ARWR's consensus EPS is -1.55, and IONS beat EPS and revenue estimates. CRSP showed Phase 1b data, and VKTX's next earnings are tentatively Feb 10, 2027.
How this was made
The 30-second read
Why it matters
The most actionable items are CYTK’s Nov 14 FDA PDUFA decision and ARWR’s Nov 12 after-hours earnings, while CRSP’s newly reported CTX310 Phase 1b data and RMAT designations provide a near-term narrative catalyst. Several other same-day moves (IONS, VKTX) are flagged as lacking an identified explanation in the scraped sources, increasing uncertainty.
Market read
Event-driven trading focus for US mid-cap biotech names, with a clear FDA decision date and earnings timing plus newly reported clinical/regulatory updates.
What to watch
For CYTK, ARWR, IONS, and VKTX, the key missing piece is forward guidance and cash runway/dilution risk; for CRSP, the market may focus on endpoint strength and next trial design details not provided in this text.
Background
A mid-cap biotech catalyst screen lists five US-listed names with upcoming FDA dates, earnings, and pipeline data, emphasizing binary event risk and how much good news may already be priced in.
Ticker impact
Cytokinetics faces an FDA PDUFA decision on Nov 14 for label expansion tied to the MAPLE-HCM study, with a stock move after Q3 revenue beat.
Likely volatility into the Nov 14 FDA decision as traders reprice approval odds versus the already-strong post-Q3 narrative.
The article specifies the Nov 14 PDUFA date, the study basis for label expansion, and notes the stock fell after the Q3 print, implying expectations were not uniformly bullish.
Arrowhead reports earnings Nov 12 after hours with consensus EPS -1.55 and revenue $59.19M, after a sharp pre-print drop of 15.84%.
Likely two-way reaction after-hours as results and guidance determine whether the selloff was overdone or justified.
The article provides the earnings date and consensus numbers but does not explain the magnitude of the prior selloff or any specific guidance change.
Ionis posted Q3 EPS $0.66 versus -$1.21 expected and revenue $243M versus $183M expected, yet the stock is down 23.21% with no resolved catalyst.
Near-term downside pressure or continued choppiness until the market clarifies what drove the selloff despite the beat.
The article includes the beat and the same-day drawdown but explicitly says no explanation or dated upcoming catalyst was found, limiting confidence on direction.
CRISPR is tied to fresh CTX310 Phase 1b data showing triglyceride lowering in severe hypertriglyceridemia, plus FDA RMAT designations for two indications.
Potential upward bias as traders price improved regulatory pathway and development momentum from the newly reported data.
The article states the data and RMAT designations were reported in the release, but it does not quantify effect size or provide additional context on durability or endpoints.
Viking reported Q3 EPS -1.55 versus -1.06 expected, yet the stock rose 8.08% on the print, with no cause identified in the sources pulled.
Likely continued volatility as traders seek the missing explanation for the positive reaction versus the EPS miss.
The article provides the EPS numbers and the same-day stock move but states no cause was found, making directional inference weak.
Market effects
Highlights typical mid-cap biotech catalyst clustering, where binary FDA dates and earnings prints drive outsized repricing and volatility.
US biotech tape focus, with event-driven trading likely concentrated in after-hours and pre-decision windows.
Limited direct global spillover, but FDA-related sentiment can influence broader biotech risk appetite.
Counterpoint
The article frames several moves as unexplained, so price action may reflect factors not captured here (guidance, cash runway, dilution expectations), meaning traders should not assume the stated catalysts fully explain direction.
Key entities
- companyCytokinetics
FDA PDUFA decision on Nov 14 for label expansion tied to MAPLE-HCM, with a supplemental application planned for Q4 2026.
- companyArrowhead
Earnings scheduled Nov 12 after hours with consensus EPS -1.55 and revenue $59.19M.
- companyIonis
Q3 beat on EPS and revenue, but shares down 23.21% with no catalyst explanation found in the sources.
- companyCRISPR Therapeutics
CTX310 Phase 1b data and FDA RMAT designations for two indications reported in the release.
- companyViking Therapeutics
Q3 EPS miss (-1.55 vs -1.06 expected) but shares up 8.08% on the print, with no cause identified in the sources pulled.
